Home / Stocks / Brooks Lab Limited
BROOKS

Brooks Lab Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹67.3

Change

+0.34 (0.51%)

Open

₹67.15

Prev. Close

₹66.96

Day High

₹69.7

Day Low

₹66.21

Volume Analysis

Traded

94,907

Delivered

39,054

Delivery %

41.15%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong return on equity (22.0%)

Weaknesses (2)

  • •Promoter holding is falling
  • •Low operating margin (-2.5%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹72.76 ₹71.23 ₹69.27 ₹67.74 ₹65.78 ₹64.25 ₹62.29
Fibonacci ₹71.23 ₹69.9 ₹69.07 ₹67.74 ₹66.41 ₹65.58 ₹64.25
Camarilla ₹68.26 ₹67.94 ₹67.62 ₹67.74 ₹66.98 ₹66.66 ₹66.34

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-13.31%

1 Week

+1.99%

1 Month

+10.73%

3 Months

+12.17%

6 Months

+25.26%

1 Year

-36.0%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹109.59

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

41.81%

Net margin 92.41% × asset turnover 0.39x × equity multiplier 1.16x

Company Overview

Sector

Healthcare

Market Cap

₹203 Cr

P/E (TTM)

58.7

ROE

22.0%

Book Value

₹64.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Brooks Lab Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Financial Strength (100/100), while Risk & Volatility (8/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.0%); promoter holding is falling; low operating margin (-2.5%).

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

33

Valuation

49

Cash Flow

44

Corporate Governance

43

Momentum

45

Institutional Ownership

47

Business Quality

74

Risk & Volatility

8

Liquidity

29

From Screener.in

  • +Company is almost debt free.
  • +Stock is trading at 1.09 times its book value
  • +Company has delivered good profit growth of 26.6% CAGR over last 5 years
  • −The company has delivered a poor sales growth of 2.11% over past five years.
  • −Company has a low return on equity of -2.02% over last 3 years.
  • −Contingent liabilities of Rs.123 Cr.
  • −Earnings include an other income of Rs.82.5 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

CARE upgraded Brooks Laboratories’ ratings; received ₹106.33 crore from stake sale, becoming net debt free.

Brooks Laboratories Limited has informed about copy of Newspaper Publication.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 24 22 18 18 21 21 23 26 23 17 20 23 19
Expenses + 25 25 27 20 24 22 25 22 21 16 20 24 21
Operating Profit -1 -3 -10 -2 -3 -2 -1 3 3 1 1 -1 -2
OPM % -4.5% -15.0% -54.0% -11.0% -16.0% -7.0% -5.0% 12.0% 11.0% 4.4% 3.4% -6.0% -11.0%
Other Income + 0 0 1 0 0 0 1 7 6 5 1 0 76
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit before tax -2 -4 -10 -2 -4 -2 -1 10 8 6 2 -2 73
Tax % 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% 14.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.0%
Net Profit + -2 -4 -10 -2 -4 -2 -1 10 8 6 2 -2 68
EPS in Rs -1 -1 -4 -1 -2 -1 -1 3 3 2 1 -1 23
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 35 42 41 14 -15 -6 32 42 13 -19 -13 -10 -18

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 77 91 63 79 83 86 79
Expenses + 77 105 93 97 91 79 81
Operating Profit 1 -14 -30 -18 -8 7 -2
OPM % 0.7% -16.0% -47.0% -22.0% -10.0% 8.0% -2.5%
Other Income + 1 1 1 1 1 20 83
Interest 3 3 2 1 1 1 1
Depreciation 7 7 7 2 2 2 2
Profit before tax -9 -24 -38 -20 -10 25 78
Tax % 115.0% -19.0% -19.0% 0.0% 2.0% 0.0% —
Net Profit + -19 -19 -31 -20 -10 25 73
EPS in Rs -8 -5 -8 -7 -3 8 25
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 18 -31 26 4 4 -15

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 54 63 49 39 69 93 159
Borrowings + 31 25 7 6 8 9 7
Other Liabilities + 52 83 29 19 18 17 22
Total Liabilities 162 196 110 90 124 148 218
Fixed Assets + 108 110 15 14 14 15 16
CWIP 1 15 0 0 0 1 2
Investments 0 0 64 43 74 92 87
Other Assets + 54 71 31 34 36 40 112
Total Assets 162 196 110 90 124 148 218
Equity Capital 25 25 25 26 29 29 29

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 4 -37 -14 -10 3 9
Cash from Investing Activity + -5 -25 0 0 -45 -3
Cash from Financing Activity + 1 64 11 10 42 0
Net Cash Flow 0 2 -3 0 0 7
Free Cash Flow -1 -62 -15 -10 2 6
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 1,519 261 48 56 -26 131

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 63.59% → 52.62%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 32.56% 32.55% 32.55% 32.53% 37.08% 36.95% 37.0% 37.0% 36.91% 36.84% 37.0% 36.84%
Promoters 63.59% 63.59% 63.59% 63.59% 59.06% 52.62% 52.62% 52.62% 52.62% 52.62% 52.62% 52.62%
FII 0.0% 0.0% 0.0% 0.02% 0.01% 0.05% 0.0% 0.01% 0.09% 0.17% 0.0% 0.04%
DII 3.86% 3.86% 3.86% 3.86% 3.86% 10.38% 10.38% 10.38% 10.38% 10.38% 10.38% 10.5%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Brooks Lab Limited (this stock) 203 58.7 1.08 22.0%
Bilcare Ltd. 202 5.55 1.13 1.39%
Nectar Lifesciences Ltd. 193 — 0.34 -31.3%
Take Limited 192 22.0 5.6 16.5%
Balaxi Pharma Ltd 175 51.8 0.69 0.59%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Natural Capsules Limited 144 — 0.66 -9.45%

Which Mutual Funds Hold Brooks Lab Limited?

Frequently Asked Questions about Brooks Lab Limited

Community Sentiment

What are other investors saying about Brooks Lab Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.